Clinical Trials Details

S2302 Pragmatica (Lung)

A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Objective

Key eligibility: Received 1 anti PD-1/PD-L1 for advanced disease; progression >84 days after C1D1; must have progressed on platinum chemo

Learn more about this trial:

• ClinicalTrials.gov
• National Cancer Institute

Clinical Trial Categories

• Cancers and Other Neoplasms